<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ARESTIN- minocycline hydrochlorideÂ powderÂ </strong><br>OraPharma, Inc.<br></p></div>
<h1>
<span class="Bold">ARESTIN<span class="Sup">Â®</span></span><br><span class="Bold">(minocycline hydrochloride) Microspheres, 1 mg </span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e16f6ae3-1a79-4363-9e7e-cdaef642b6a5"></a><a name="section-1"></a><p></p>
<p class="First">Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_28409895-eef8-479e-9863-1fec6c1da5bd"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION </h1>
<p class="First">ARESTIN<span class="Sup">Â®</span> (minocycline hydrochloride) Microspheres is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subgingival administration into periodontal pockets. Each unit-dose cartridge delivers minocycline hydrochloride equivalent to 1 mg of minocycline free base.</p>
<p>The molecular formula of minocycline hydrochloride is C<span class="Sub">23</span>H<span class="Sub">27</span>N<span class="Sub">3</span>O<span class="Sub">7 </span>â—? HCl, and the molecular weight is 493.94. The structural formula of minocycline hydrochloride is:</p>
<div class="Figure">
<a name="id-1310169671"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8515df41-1936-4f3b-86ba-d2bb2a8441fb&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_181cdbd7-abbc-468c-b719-58978bd78ad3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_a78f98e5-2f13-4a8c-b321-1c73ce3006fb"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The mechanism of action of ARESTIN<span class="Sup">Â®</span> as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2626d52-382b-43e2-a4f8-647ffff6dc4c"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Minocycline, a member of the tetracycline class of antibiotics, has a broad spectrum of activity.<span class="Sup">1</span> It is bacteriostatic and exerts its antimicrobial activity by inhibiting protein synthesis.<span class="Sup">1</span> In vitro susceptibility testing has shown that the organisms <span class="Italics">Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, Eikenella corrodens</span>, and <span class="Italics">Actinobacillus actinomycetemcomitans</span>, which are associated with <span class="product-label-link" type="condition" conceptid="134398" conceptname="Periodontal disease">periodontal disease</span>, are susceptible to minocycline at concentrations of â‰¤8 mcg/mL<span class="Sup">2</span>; qualitative and quantitative changes in plaque microorganisms have not been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span>, using this product.</p>
<p>The emergence of minocycline-resistant bacteria in single-site plaque samples was studied in subjects before and after treatment with ARESTIN<span class="Sup">Â®</span> at 2 centers. There was a slight increase in the numbers of minocycline-resistant bacteria at the end of the 9-month study period, however, the number of subjects studied was small and the clinical significance of these findings is unknown.</p>
<p>The emergence of minocycline-resistant bacteria and changes in the presence of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> and <span class="Italics">Staphylococcus aureus</span> in the gastrointestinal tract were studied in subjects treated with ARESTIN<span class="Sup">Â®</span> in one phase 3 study. No changes in the presence of minocycline-resistant bacteria or <span class="Italics">C. albicans</span> or <span class="Italics">S. aureus</span> were seen at the end of the 56-day study period.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_24bc809a-92ae-42f3-ac74-580588b683de"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In a pharmacokinetic study, 18 patients (10 men and 8 women) with moderate to advanced chronic <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span> were treated with a mean dose of 46.2 mg (25 to 112 unit doses) of ARESTIN<span class="Sup">Â®</span>. After fasting for at least 10 hours, patients received subgingival application of ARESTIN<span class="Sup">Â®</span> (1 mg per treatment site) following scaling and root planing at a minimum of 30 sites on at least 8 teeth. Investigational drug was administered to all eligible sites â‰¥5 mm in probing depth. Mean dose normalized saliva AUC and Cmax were found to be approximately 125 and 1000 times higher than those of serum parameters, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_902bc09d-4e1f-4e86-a940-c1aee978f7e6"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Studies </h2>
<p class="First">In 2 well-controlled, multicenter, investigator-blind, vehicle-controlled, parallel-design studies (3 arms), 748 patients (study OPI-103A = 368, study OPI-103B = 380) with generalized moderate to advanced adult <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span> characterized by a mean probing depth of 5.90 and 5.81 mm, respectively, were enrolled. Subjects received 1 of 3 treatments: (1) scaling and root planing, (2) scaling and root planing + vehicle (bioresorbable polymer, PGLA), and (3) scaling and root planing + ARESTIN<span class="Sup">Â®</span>. To qualify for the study, patients were required to have 4 teeth with periodontal pockets of 6 to 9 mm that bled on probing. However, treatment was administered to all sites with mean probing depths of 5 mm or greater. Patients studied were in good general health. Patients with poor glycemic control or active infectious diseases were excluded from the studies. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth â‰¥5 mm also received treatment. Patients treated with ARESTIN<span class="Sup">Â®</span> were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment, as shown in <a href="#_Reftable1">Table 1</a>.</p>
<a name="_Reftable1"></a><table width="85%">
<caption><span>Table 1: Probing Pocket Depth at Baseline and Change in Pocket Depth at 9 Months from 2 Multicenter US Clinical Trials </span></caption>
<col width="13%">
<col width="11%">
<col width="12%">
<col width="14%">
<col width="11%">
<col width="12%">
<col width="14%">
<thead>
<tr class="First">
<th class="Toprule" align="center" valign="bottom"><span class="Bold">Time</span></th>
<th class="Toprule" align="center" colspan="4" valign="top">
<span class="Bold">Study OPI-103A </span><br><span class="Bold">N=368</span>
</th>
<th class="Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Study OPI-103B </span><br><span class="Bold">N=380</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone </span><br><span class="Bold">n=124</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle n=123</span>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span> n=121</span></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone </span><br><span class="Bold">n=126</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle n=126</span>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span> n=128</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="7" valign="top">SE = standard error; SRP = scaling and root planing; PD = pocket depth.</td></tr>
<tr><td class="Botrule" align="left" colspan="7" valign="top">Significantly different from SRP: *(P â‰¤0.05); **(P â‰¤0.001). </td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="7" valign="top">Significantly different from SRP + vehicle: <span class="Sup">â€ </span>(P â‰¤0.05); <span class="Sup">â€ â€ </span>(P â‰¤0.001). </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">PD (mm) at Baseline,</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.88Â±</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.91Â±</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.88Â±</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.79Â±</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.82Â±</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">5.81Â±</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Mean Â± SE</p></td>
<td class="Botrule" align="center"><p class="First">0.04</p></td>
<td class="Botrule" align="center"><p class="First">0.04</p></td>
<td class="Botrule" align="center"><p class="First">0.04</p></td>
<td class="Botrule" align="center"><p class="First">0.03</p></td>
<td class="Botrule" align="center"><p class="First">0.04</p></td>
<td class="Botrule" align="center"><p class="First">0.04</p></td>
</tr>
<tr>
<td><p class="First">PD (mm) Change From Baseline</p></td>
<td align="center" valign="middle"><p class="First">-1.04</p></td>
<td align="center" valign="middle"><p class="First">-0.90</p></td>
<td align="center" valign="middle"><p class="First">-1.20*â€ â€ </p></td>
<td align="center" valign="middle"><p class="First">-1.32</p></td>
<td align="center" valign="middle"><p class="First">-1.30</p></td>
<td align="center" valign="middle"><p class="First">-1.63**â€ â€ </p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">at 9 Months, <br>Mean Â± SE</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.07</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.54</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.07</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.07</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.07</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Â±0.07</p></td>
</tr>
</tbody>
</table>
<p>In these 2 studies, an average of 29.5 (5-114), 31.7 (4-137), and 31 (5-108) sites were treated at baseline in the SRP alone, SRP + vehicle, and SRP + ARESTIN<span class="Sup">Â®</span> groups, respectively. When these studies are combined, the mean pocket depth change at 9 months was -1.18 mm, -1.10 mm, and -1.42 mm for SRP alone, SRP + vehicle, and SRP + ARESTIN<span class="Sup">Â®</span>, respectively.</p>
<a name="_Reftable2"></a><table width="85%">
<caption><span>Table 2: Numbers (percentage) of Pockets Showing a Change of Pocket Depth â‰¥2 mm at 9 Months from 2 Multicenter US Clinical Trials </span></caption>
<col width="12%">
<col width="11%">
<col width="11%">
<col width="14%">
<col width="11%">
<col width="11%">
<col width="14%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Study OPI-103A</span></th>
<th class="Botrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Study OPI-103B</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle</span>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span></span></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle</span>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span></span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Pockets</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">1046</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">927</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">1326</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">1692</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">1710</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">2082</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">â‰¥2 mm <br>(% of total)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(31.1%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(25.7%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(36.5%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(42.2%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(40.0%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(51.0%)</p></td>
</tr>
<tr>
<td><p class="First">Pockets</p></td>
<td align="center" valign="middle"><p class="First">417</p></td>
<td align="center" valign="middle"><p class="First">315</p></td>
<td align="center" valign="middle"><p class="First">548</p></td>
<td align="center" valign="middle"><p class="First">553</p></td>
<td align="center" valign="middle"><p class="First">524</p></td>
<td align="center" valign="middle"><p class="First">704</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">â‰¥3 mm <br>(% of total)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(12.4%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(8.7%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(15.1%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(13.8%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(12.3%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(17.3%)</p></td>
</tr>
</tbody>
</table>
<p>SRP + ARESTIN<span class="Sup">Â®</span> resulted in a greater percentage of pockets showing a change of PD â‰¥2 mm and â‰¥3 mm compared to SRP alone at 9 months, as shown in <a href="#_Reftable2">TABLE 2</a>.</p>
<a name="_Reftable3"></a><table width="85%">
<caption><span>Table 3: Mean Pocket Depth Changes (SE) in Subpopulations, Studies 103A and 103B Combined </span></caption>
<col width="33%">
<col width="17%">
<col width="17%">
<col width="18%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">ARESTIN<span class="Sup">Â®</span></span>
</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="18" valign="top">SRP = scaling and root planing; YOA = years of age; CV = cardiovascular</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>SRP vs SRP + ARESTIN<span class="Sup">Â® </span>P â‰¤0.05</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>SRP vs SRP + ARESTIN<span class="Sup">Â®</span><span class="Italics"></span>P â‰¤0.001</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Smokers</p></td>
<td class="Toprule"><p class="First">n = 91</p></td>
<td class="Toprule"><p class="First">n = 90</p></td>
<td class="Toprule"><p class="First">n = 90</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-0.96Â±</p></td>
<td><p class="First">-0.98Â±</p></td>
<td><p class="First">-1.24Â±</p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.09 mm</p></td>
<td class="Botrule"><p class="First">0.07 mm</p></td>
<td class="Botrule"><p class="First">0.09 mm<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">Nonsmokers</span> </p></td>
<td><p class="First">n = 159</p></td>
<td><p class="First">n = 159</p></td>
<td><p class="First">n = 159</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-1.31Â±</p></td>
<td><p class="First">-1.17Â±</p></td>
<td><p class="First">-1.53Â±</p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.06 mm </p></td>
<td class="Botrule"><p class="First">0.07 mm </p></td>
<td class="Botrule"><p class="First">0.06 mm<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First">Patients &gt;50 YOA </p></td>
<td><p class="First">n = 21</p></td>
<td><p class="First">n = 81</p></td>
<td><p class="First">n = 107</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-1.07Â±</p></td>
<td><p class="First">-0.92Â±</p></td>
<td><p class="First">-1.42Â±</p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.09 mm </p></td>
<td class="Botrule"><p class="First">0.08 mm </p></td>
<td class="Botrule"><p class="First">0.08 mm<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First">Patients â‰¤50 YOA </p></td>
<td><p class="First">n = 167</p></td>
<td><p class="First">n = 168</p></td>
<td><p class="First">n = 142</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-1.24Â±</p></td>
<td><p class="First">-1.19Â±</p></td>
<td><p class="First">-1.43Â±</p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.06 mm </p></td>
<td class="Botrule"><p class="First">0.06 mm </p></td>
<td class="Botrule"><p class="First">0.07 mm<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
</tr>
<tr>
<td><p class="First">Patients with CV Disease </p></td>
<td><p class="First">n = 36</p></td>
<td><p class="First">n = 29</p></td>
<td><p class="First">n = 36</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-0.99Â±</p></td>
<td><p class="First">-1.06Â±</p></td>
<td><p class="First">-1.56Â±</p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.13 mm </p></td>
<td class="Botrule"><p class="First">0.14 mm </p></td>
<td class="Botrule"><p class="First">0.14 mm<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td><p class="First">Patients w/o CV Disease</p></td>
<td><p class="First">n = 214</p></td>
<td><p class="First">n = 220</p></td>
<td><p class="First">n = 213</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">-1.22Â±</p></td>
<td><p class="First">-1.11Â±</p></td>
<td><p class="First">-1.40Â±</p></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td class="Botrule"><p class="First">0.06 mm </p></td>
<td class="Botrule"><p class="First">0.05 mm </p></td>
<td class="Botrule"><p class="First">0.06 mm<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
</tbody>
</table>
<p>In both studies, the following patient subgroups were prospectively analyzed: smokers, patients over and under 50 years of age, and patients with a previous history of cardiovascular disease. The results of the combined studies are presented in <a href="#_Reftable3">Table 3</a>.</p>
<p>In smokers, the mean reduction in pocket depth at 9 months was less in all treatment groups than in <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>, but the reduction in mean pocket depth at 9 months with SRP + ARESTIN<span class="Sup">Â®</span> was significantly greater than with SRP + vehicle or SRP alone.</p>
<a name="_Reftable4"></a><table width="90%">
<caption><span>Table 4: Mean Pocket Depth Change in Patients with Mean Baseline PD â‰¥5 mm, â‰¥6 mm, and â‰¥7 mm at 9 Months from 2 Multicenter US Clinical Trials</span></caption>
<col width="14%">
<col width="12%">
<col width="12%">
<col width="14%">
<col width="12%">
<col width="12%">
<col width="14%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Study OPI-103A</span></th>
<th class="Botrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Study OPI-103B</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center" valign="middle">
<span class="Bold">Mean Baseline </span><br><span class="Bold">Pocket Depth</span>
</th>
<th class="Botrule" align="center" valign="middle">
<span class="Bold">SRP </span><br><span class="Bold">Alone</span>
</th>
<th class="Botrule" align="center" valign="middle"><span class="Bold">SRP + Vehicle</span></th>
<th class="Botrule" align="center" valign="middle"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span></span></th>
<th class="Botrule" align="center" valign="middle">
<span class="Bold">SRP </span><br><span class="Bold">Alone</span>
</th>
<th class="Botrule" align="center" valign="middle"><span class="Bold">SRP + Vehicle</span></th>
<th class="Botrule" align="center" valign="middle"><span class="Bold">SRP + ARESTIN<span class="Sup">Â®</span></span></th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Statistically significant comparison between SRP + ARESTIN<span class="Sup">Â®</span> and SRP alone</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="center"><p class="First">â‰¥5 mm (n)</p></td>
<td class="Toprule" align="center"><p class="First">-1.04 mm</p></td>
<td class="Toprule" align="center"><p class="First">-0.90 mm</p></td>
<td class="Toprule" align="center"><p class="First">-1.20 mm<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Toprule" align="center"><p class="First">-1.32 mm</p></td>
<td class="Toprule" align="center"><p class="First">-1.30 mm</p></td>
<td class="Toprule" align="center"><p class="First">-1.63 mm<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">(124)</p></td>
<td class="Botrule" align="center"><p class="First">(123)</p></td>
<td class="Botrule" align="center"><p class="First">(121)</p></td>
<td class="Botrule" align="center"><p class="First">(126)</p></td>
<td class="Botrule" align="center"><p class="First">(126)</p></td>
<td class="Botrule" align="center"><p class="First">(128)</p></td>
</tr>
<tr>
<td align="center"><p class="First">â‰¥6 mm (n)</p></td>
<td align="center"><p class="First">-0.91 mm</p></td>
<td align="center"><p class="First">-0.77 mm</p></td>
<td align="center"><p class="First">-1.40 mm<a href="#footnote-3" class="Sup">*</a></p></td>
<td align="center"><p class="First">-1.33 mm</p></td>
<td align="center"><p class="First">-1.46 mm</p></td>
<td align="center"><p class="First">-1.69 mm<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">(34)</p></td>
<td class="Botrule" align="center"><p class="First">(46)</p></td>
<td class="Botrule" align="center"><p class="First">(45)</p></td>
<td class="Botrule" align="center"><p class="First">(37)</p></td>
<td class="Botrule" align="center"><p class="First">(40)</p></td>
<td class="Botrule" align="center"><p class="First">(25)</p></td>
</tr>
<tr>
<td align="center"><p class="First">â‰¥7 mm (n)</p></td>
<td align="center"><p class="First">-1.10 mm</p></td>
<td align="center"><p class="First">-0.46 mm</p></td>
<td align="center"><p class="First">-1.91 mm</p></td>
<td align="center"><p class="First">-1.72 mm</p></td>
<td align="center"><p class="First">-1.11 mm</p></td>
<td align="center"><p class="First">-2.84 mm</p></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">(4)</p></td>
<td class="Botrule" align="center"><p class="First">(5)</p></td>
<td class="Botrule" align="center"><p class="First">(3)</p></td>
<td class="Botrule" align="center"><p class="First">(3)</p></td>
<td class="Botrule" align="center"><p class="First">(3)</p></td>
<td class="Botrule" align="center"><p class="First">(2)</p></td>
</tr>
</tbody>
</table>
<p>The combined data from these 2 studies also show that for pockets 5 mm to 7 mm at baseline, greater reductions in pocket depth occurred in pockets that were deeper at baseline.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_ba8699f5-e00f-4b52-8570-4af39f15ea2e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USE </h1>
<p class="First">ARESTIN<span class="Sup">Â®</span> is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span>. ARESTIN<span class="Sup">Â®</span> may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_fd5621b5-bfce-4ed3-9eae-8097202e79e8"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">ARESTIN<span class="Sup">Â®</span> should not be used in any patient who has a known sensitivity to minocycline or tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<p class="First">THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY BROWN). This adverse reaction is more common during long-term use of the drugs, but has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, OR IN PREGNANT OR NURSING WOMEN, UNLESS THE POTENTIAL BENEFITS ARE CONSIDERED TO OUTWEIGH THE POTENTIAL RISKS. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_f7f2363d-63d8-4e85-aadf-cf3d7836f75e"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8e574e45-5dcc-4f68-9741-cd3d4dcf9cc6"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> that included, but were not limited to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> have been reported with the use of ARESTIN<span class="Sup">Â®</span>. Some of these reactions were serious. Post-marketing cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported with oral minocycline.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_74d8b714-0ecd-4757-8b24-4539c934e1f5"></a><a name="section-7.2"></a><p></p>
<h2>Autoimmune Syndromes</h2>
<dl>
<dt>Â </dt>
<dd>Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a Lupus-like syndrome manifested by <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. Sporadic cases of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> have presented shortly after oral minocycline use, manifested by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. No further treatment with ARESTIN<span class="Sup">Â®</span> should be administered to the patient.</dd>
</dl>
<p class="First">The use of ARESTIN<span class="Sup">Â®</span> in an acutely abscessed periodontal pocket has not been studied and is not recommended.</p>
<p>While no overgrowth by opportunistic microorganisms, such as yeast, were noted during clinical studies, as with other antimicrobials, the use of ARESTIN<span class="Sup">Â®</span> may result in overgrowth of non-susceptible microorganisms including fungi. The effects of treatment for greater than 6 months has not been studied.</p>
<p>ARESTIN<span class="Sup">Â®</span> should be used with caution in patients having a history of predisposition to <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>. The safety and effectiveness of ARESTIN<span class="Sup">Â®</span> has not been established for the treatment of <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span> in patients with coexistent <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>.</p>
<p>ARESTIN<span class="Sup">Â®</span> has not been clinically tested in immunocompromised patients (such as those immunocompromised by <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, chemotherapy, radiation therapy, or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with HIV).</p>
<p>If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> is suspected, appropriate measures should be taken.</p>
<p>ARESTIN<span class="Sup">Â®</span> has not been clinically tested in pregnant women.</p>
<p>ARESTIN<span class="Sup">Â®</span> has not been clinically tested for use in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_9ad96b8f-0403-446b-97e1-764312ee0367"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients </h2>
<p class="First">After treatment, patients should avoid chewing hard, crunchy, or sticky foods (i.e., carrots, taffy, and gum) with the treated teeth for 1 week, as well as avoid touching treated areas. Patients should also postpone the use of interproximal cleaning devices around the treated sites for 10 days after administration of ARESTIN<span class="Sup">Â®</span>. Patients should be advised that although some mild to moderate sensitivity is expected during the first week after SRP and administration of ARESTIN<span class="Sup">Â®</span>, they should notify the dentist promptly if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or other problems occur. Patients should be notified to inform the dentist if <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>, reddening, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, or other signs and symptoms of possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_8328f08b-cf49-4c81-a6bd-81f7646012f6"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenicity, Mutagenicity, Impairment of Fertility </h2>
<p class="First">Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span> production. Minocycline has also been found to produce <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Minocycline demonstrated no potential to cause genetic toxicity in a battery of assays which included a bacterial reverse mutation assay (Ames test), an in vitro mammalian cell gene mutation test (L5178Y/TK<span class="Sup">+/-</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay), an in vitro mammalian chromosome aberration test, and an in vivo micronucleus assay conducted in ICR mice.</p>
<p>Fertility and general reproduction studies have provided evidence that minocycline impairs fertility in male rats.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_716b5027-e780-4c16-9229-08e1501a3dd3"></a><a name="section-7.5"></a><p></p>
<h2>Teratogenic Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ab6fd7cf-efca-480b-97e7-66acb8ffcebc"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category D.</span></h3>
<p class="First">(See <span class="Bold"><a href="#warnings">WARNINGS</a>.</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_bb67be8f-cc6c-4808-8e12-6150167c393e"></a><a name="section-7.6"></a><p></p>
<h2>Labor and Delivery </h2>
<p class="First">The effects of tetracyclines on labor and delivery are unknown. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_2a1edd28-ae8f-4e17-89a4-69ae53a4ac8e"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. (See <span class="Bold"><a href="#warnings">WARNINGS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_151f6b16-16cd-4302-932d-a6c9603282d3"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use </h2>
<p class="First">Since adult <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontitis</span> does not affect children, the safety and effectiveness of ARESTIN<span class="Sup">Â®</span> in pediatric patients cannot be established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_bf586ec8-baea-4d4a-8a0d-3f8fa92eafb2"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported nondental treatment-emergent adverse events in the 3 multicenter US trials were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<a name="_Reftable5"></a><table width="85%">
<caption><span>Table 5: Adverse Events (AEs) Reported in â‰¥3% of the Combined Clinical Trial Population of 3 Multicenter US Trials by Treatment Group </span></caption>
<col width="33%">
<col width="17%">
<col width="17%">
<col width="18%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP </span><br><span class="Bold">Alone </span><br><span class="Bold">N=250</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">Vehicle </span><br><span class="Bold">N=249</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">SRP + </span><br><span class="Bold">ARESTIN<span class="Sup">Â®</span></span><br><span class="Bold">N=423</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule"><p class="First">Number (%) of Patients Treatment-emergent AEs</p></td>
<td class="Botrule Toprule" align="center"><p class="First">62.4%</p></td>
<td class="Botrule Toprule" align="center"><p class="First">71.9%</p></td>
<td class="Botrule Toprule" align="center"><p class="First">68.1%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Total Number of AEs</p></td>
<td class="Botrule" align="center"><p class="First">543</p></td>
<td class="Botrule" align="center"><p class="First">589</p></td>
<td class="Botrule" align="center"><p class="First">987</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">Periodontitis</span> </p></td>
<td class="Botrule" align="center"><p class="First">25.6%</p></td>
<td class="Botrule" align="center"><p class="First">28.1%</p></td>
<td class="Botrule" align="center"><p class="First">16.3%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth Disorder</span> </p></td>
<td class="Botrule" align="center"><p class="First">12.0%</p></td>
<td class="Botrule" align="center"><p class="First">13.7%</p></td>
<td class="Botrule" align="center"><p class="First">12.3%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">Tooth Caries</span> </p></td>
<td class="Botrule" align="center"><p class="First">9.2%</p></td>
<td class="Botrule" align="center"><p class="First">11.2%</p></td>
<td class="Botrule" align="center"><p class="First">9.9%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â Dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td class="Botrule" align="center"><p class="First">8.8%</p></td>
<td class="Botrule" align="center"><p class="First">8.8%</p></td>
<td class="Botrule" align="center"><p class="First">9.9%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span> </p></td>
<td class="Botrule" align="center"><p class="First">7.2%</p></td>
<td class="Botrule" align="center"><p class="First">8.8%</p></td>
<td class="Botrule" align="center"><p class="First">9.2%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule" align="center"><p class="First">7.2%</p></td>
<td class="Botrule" align="center"><p class="First">11.6%</p></td>
<td class="Botrule" align="center"><p class="First">9.0%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </p></td>
<td class="Botrule" align="center"><p class="First">8.0%</p></td>
<td class="Botrule" align="center"><p class="First">9.6%</p></td>
<td class="Botrule" align="center"><p class="First">7.6%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> </p></td>
<td class="Botrule" align="center"><p class="First">8.4%</p></td>
<td class="Botrule" align="center"><p class="First">6.8%</p></td>
<td class="Botrule" align="center"><p class="First">6.4%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">Mouth Ulceration</span> </p></td>
<td class="Botrule" align="center"><p class="First">1.6%</p></td>
<td class="Botrule" align="center"><p class="First">3.2%</p></td>
<td class="Botrule" align="center"><p class="First">5.0%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span> </p></td>
<td class="Botrule" align="center"><p class="First">3.2%</p></td>
<td class="Botrule" align="center"><p class="First">6.4%</p></td>
<td class="Botrule" align="center"><p class="First">5.0%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule" align="center"><p class="First">3.2%</p></td>
<td class="Botrule" align="center"><p class="First">1.6%</p></td>
<td class="Botrule" align="center"><p class="First">4.3%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule" align="center"><p class="First">4.0%</p></td>
<td class="Botrule" align="center"><p class="First">1.2%</p></td>
<td class="Botrule" align="center"><p class="First">4.3%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule" align="center"><p class="First">2.0%</p></td>
<td class="Botrule" align="center"><p class="First">0</p></td>
<td class="Botrule" align="center"><p class="First">4.0%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Dental </p></td>
<td class="Botrule" align="center"><p class="First">4.0%</p></td>
<td class="Botrule" align="center"><p class="First">3.6%</p></td>
<td class="Botrule" align="center"><p class="First">3.8%</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">Mucous Membrane Disorder</span> </p></td>
<td class="Botrule" align="center"><p class="First">2.4%</p></td>
<td class="Botrule" align="center"><p class="First">0.8%</p></td>
<td class="Botrule" align="center"><p class="First">3.3%</p></td>
</tr>
</tbody>
</table>
<p>The change in clinical attachment levels was similar across all study arms, suggesting that neither the vehicle nor ARESTIN<span class="Sup">Â®</span> compromise clinical attachment. <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_c8ecd300-e3be-45f3-8769-31b7a25412e7"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First">ARESTIN<span class="Sup">Â®</span> is provided as a dry powder, packaged in a unit dose cartridge with a deformable tip (see Figure 1), which is inserted into a spring-loaded cartridge handle mechanism (see Figure 2) to administer the product.</p>
<p>The oral health care professional removes the disposable cartridge from its pouch and connects the cartridge to the handle mechanism (see Figures 3-4). ARESTIN<span class="Sup">Â®</span> is a variable dose product, dependent on the size, shape, and number of pockets being treated. In US clinical trials, up to 122 unit dose cartridges were used in a single visit and up to 3 treatments, at 3-month intervals, were administered in pockets with pocket depth of 5 mm or greater.</p>
<div class="Figure">
<a name="id718638763"></a><img alt="Arestin figures" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8515df41-1936-4f3b-86ba-d2bb2a8441fb&amp;name=Arestin%20figures.jpg">
</div>
<p>The administration of ARESTIN<span class="Sup">Â®</span> does not require local anesthesia. Professional subgingival administration is accomplished by inserting the unit-dose cartridge to the base of the periodontal pocket and then pressing the thumb ring in the handle mechanism to expel the powder while gradually withdrawing the tip from the base of the pocket. The handle mechanism should be sterilized between patients. ARESTIN<span class="Sup">Â®</span> does not have to be removed, as it is bioresorbable, nor is an adhesive or dressing required.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_cd5c21f8-7f4f-4833-b114-11a8883134c0"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED </h1>
<p class="First">ARESTIN<span class="Sup">Â®</span> (minocycline hydrochloride) Microspheres, 1 mg is supplied as follows:</p>
<dl>
<dt>â€¢</dt>
<dd>1 unit-dose cartridge with desiccant in a heat-sealed, foil-laminated pouch (NDC 65976-100-01)</dd>
<dt>â€¢</dt>
<dd>12 unit-dose cartridges in 1 tray with desiccant in a heat-sealed, foil-laminated, resealable pouch (NDC 65976-100-24). There are 2 pouches in each box.</dd>
</dl>
<p>Each unit-dose cartridge contains the product identifier "OP-1."</p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_7a1a4f64-8724-4349-bfb1-b16edfb2420b"></a><a name="section-10.1"></a><p></p>
<h2>Storage Conditions</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F)/60% RH: excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F). Avoid exposure to excessive heat.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_8486d6eb-3fe7-4caf-ac22-f4900fd5289d"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Stratton CW, Lorian V. Mechanisms of action of antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. In: <span class="Italics">Antibiotics in Laboratory Medicine</span>. 4th ed. Baltimore, MD: Williams and Wilkins; 1996.  </dd>
<dt>2.</dt>
<dd>Slots J, Rams TE. Antibiotics in periodontal therapy: advantages and disadvantages. <span class="Italics">J Clin Periodontol</span>. 1990; 17:479-493.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75b1c82d-7c42-4b90-af62-8a5c745d4c7a"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured for: </p>
<p>OraPharma, a division of Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807</p>
<p>by:</p>
<p>AAIPharma Services Corporation</p>
<p>Wilmington, NC 28405</p>
<p>Â© 2015 Valeant Pharmaceuticals North America LLC</p>
<p>9443900</p>
<p>Rev. 08/2015</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1ed82fad-5d05-4e02-8647-23017f8d8b78"></a><a name="section-13"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0da372fa-0819-43fc-9d50-718de8b1a801"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mg Carton</h1>
<p class="First"><span class="Bold">NDC</span> 65976-100-24</p>
<p><span class="Bold">Microsphere Delivery System</span><br><span class="Bold"><span class="Italics">Arestin</span></span><span class="Sup">Â®</span><br>minocycline HCl 1mg<br><span class="Bold"><span class="Italics">MICROSPHERES</span></span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F)</span><br><span class="Bold">/60% RH: excursions permitted to</span><br><span class="Bold">15Â° to 30Â°C (59Â° to 86Â°F).</span></p>
<p><span class="Bold">Avoid exposure to excessive heat</span></p>
<p><span class="Bold">For Subgingival Application</span></p>
<p><span class="Bold">Rx only</span></p>
<p>To order: Call 1-866-ARESTIN (273-7846)<br>or visit our Web site at www.ArestinProfessional.com</p>
<p><span class="Bold"><span class="Italics">ora</span>PHARMA</span></p>
<p><span class="Bold">2 resealable foil pouches</span><br><span class="Bold">12 cartridges per pouch</span><br><span class="Bold">1 mg of minocycline per cartridge</span></p>
<div class="Figure">
<a name="id-1992099395"></a><img alt="Arestin carton Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8515df41-1936-4f3b-86ba-d2bb2a8441fb&amp;name=Arestin%20Carton%20Image.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ARESTINÂ 		
					</strong><br><span class="contentTableReg">minocycline hydrochloride powder</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65976-100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Minocycline Hydrochloride</strong> (Minocycline) </td>
<td class="formItem">Minocycline</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65976-100-01</td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:65976-100-12</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">12  in 1 TRAY; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:65976-100-24</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">12  in 1 TRAY; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050781</td>
<td class="formItem">03/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>OraPharma, Inc.
							(075846118)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Valeant Pharmaceuticals North America LLC (042230623)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AAIPharma Services Corp.</td>
<td class="formItem"></td>
<td class="formItem">832395235</td>
<td class="formItem">MANUFACTURE(65976-100)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sharp Corporation</td>
<td class="formItem"></td>
<td class="formItem">143696495</td>
<td class="formItem">PACK(65976-100)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>492deeb2-cafb-4403-ba7b-662a984e3e1d</div>
<div>Set id: 8515df41-1936-4f3b-86ba-d2bb2a8441fb</div>
<div>Version: 7</div>
<div>Effective Time: 20150801</div>
</div>
</div>Â <div class="DistributorName">OraPharma, Inc.</div></p>
</body></html>
